A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.

"Conflict of Interest GML holds a consultancy position with F. Hoffmann-La Roche AG [Roche]. GML and RG hold a patent for the manufacture of regulatory T cells for the treatment of inflammatory bowel disease [PCT/GB2019/053618]."

"Funding This work was supported by an Medical Research Council grant to RGJ and GML [MR/R001413/1], and a Guts UK/forCrohns Development grant to JNC, PMI, and GML [DGC2019_02]. This research was supported by the National Institute for Health [NIHR] Biomedical Research Centres at Guy’s & St Thomas’ NHS Foundation Trust and King’s College London, and Cambridge University Hospital NHS Foundation Trust and the University of Cambridge. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health."